Vimarsana
Biggest News Aggregation in the World

Page 12 - Sleep Science News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sleep Science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sleep Science Today - Breaking & Trending Today

How to Heal When the Doctor Says There's Nothing Left to Try - Vimarsana News

How to Heal When the Doctor Says There's Nothing Left to Try

Teresa, a fit and healthy mother of four, showed up at her spinning class with some bad news. ...

Is there such a thing as the perfect alarm tone? We think so (and this is what it might sound like) - Vimarsana News

Is there such a thing as the perfect alarm tone? We think so (and this is what it might sound like)

An effective alarm is one which should minimise ‘sleep inertia’ – that stage of grogginess we feel between being asleep and becoming fully alert.

Incannex's Drug Lowers AHI for Sleep Apnea Patients in Clinical Trial - Vimarsana News

Incannex's Drug Lowers AHI for Sleep Apnea Patients in Clinical Trial

The trial assessed 3 doses of Incannex Healthcare Ltd's cannabinoid combination product IHL-42X at reducing AHI in obstructive sleep apnea.

Incannex sees up to 91.5% reduction in severity of obstructive sleep apnoea in preliminary IHL-42X clinical trial results - Vimarsana News

Incannex sees up to 91.5% reduction in severity of obstructive sleep apnoea in preliminary IHL-42X clinical trial results

Incannex Healthcare (ASX: IHL) has completed a preliminary analysis of data from a phase 2 proof-of-concept clinical trial investigating novel cannabinoid combination product IHL-42X for the treatment of obstructive sleep apnoea (OSA).

Incannex observes substantial reduction in AHI in preliminary results of clinical trial assessing IHL-42X in patients with OSA; proceeds to pivotal studies - Vimarsana News

Incannex observes substantial reduction in AHI in preliminary results of clinical trial assessing IHL-42X in patients with OSA; proceeds to pivotal studies

/PRNewswire/ -- Highlights: 20% of trial participants experienced a reduction in AHI of greater than 80% (range: 82.7% to 91.5%) during at least one treatment...